Stenting versus thrombolysis in acute myocardial infarction trial (STAT)
Michel R. Le May, MD, FACCa,
Marino Labinaz, MD, FACCa,
Richard F. Davies, MD, FACCa,
Jean-François Marquis, MDa,
Louise A. Laramée, MDa,
Edward R. O’Brien, MD, FACCa,
William L. Williams, MD, FACCa,
Rob S. Beanlands, MDa,
Graham Nichol, MDa and
Lyall A. Higginson, MD, FACCa
a Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Canada
View larger version (20K):
[in a new window]
|
Figure 1 Kaplan-Meier curves for freedom from the primary end point—death, reinfarction, stroke or repeat target vessel revascularization for ischemia within 180 days after randomization according to treatment group. t-PA = tissue plasminogen activator.
|
|
View larger version (23K):
[in a new window]
|
Figure 2 Kaplan-Meier curves for freedom from death, reinfarction, stroke or recurrent unstable ischemia within 180 days after randomization according to treatment group. t-PA = tissue-plasminogen activator.
|
|
|
